10x Genomics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
10x Genomics, Inc. (TXG) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-07
- 10x Genomics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.02M, a 9.80% increase year-over-year.
- 10x Genomics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.95M, a 8.98% increase year-over-year.
- 10x Genomics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $1.84M.
- 10x Genomics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $1.79M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month |
|---|---|---|
| 2026-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $3.97M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $1.95M 10-Q · filed 2026-05-08 | |
| 2025-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $3.63M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $1.79M 10-Q · filed 2026-05-08 |